期刊文献+

Nucleostemin和Ki-67在垂体腺瘤组织中的表达及其临床意义 被引量:2

Expressions of nucleostemin and Ki-67 in pituitary adenomas and their cfinical significance
原文传递
导出
摘要 目的研究nucleostemin基因和Ki-67抗原在垂体腺瘤中的表达,分析nucleostemin基因在垂体腺瘤细胞增殖及肿瘤发生和发展中的作用。方法收集垂体腺瘤手术标本71例,采用半定量RT-PCR方法检测垂体腺瘤标本中nucleosteminmRNA的表达情况,采用免疫组化方法检测垂体腺瘤石蜡切片中Ki-67抗原的表达情况。同时收集相关临床资料。结果本组71例垂体腺瘤手术标本均有nucleosteminmRNA表达。非侵袭性垂体腺瘤和侵袭性垂体腺瘤中nucleosteminmRNA、Ki-67标记指数(Ki-67LI)表达差异有统计学意义(P〈0.05)。复发组与未复发组中Ki-67LI表达差异有统计学意义(P〈0.05)。Nucleostemin mRNA表达水平与Ki-67LI呈正相关关系(r=0.237。P〈0.05)。结论Nucleostemin基因在人垂体腺瘤的侵袭性行为中发挥重要作用,其表达增高和Ki-67表达水平升高之间存在正相关,二者可以作为判断垂体腺瘤侵袭性和预测复发的有效临床检测指标。 Objective To study the expressions of nucleostemin gene mRNA and Ki-67 antigen in pituitary adenomas and investigate the role of nucleostemin gene in the tumorigenesis and development of pituitary adenomas. Methods Seventy-one samples of pituitary adenomas were collected. Semi-quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) was used to detect the expression of nucleostemin gene mRNA in samples. Immunohistochemistry technique was applied to examine Ki-67 antigen expression in the paraffin sections of samples. At the same time, coherent clinical data were collected. Results Nucleostemin gene mRNA was detectable in all samples of pituitary adenomas. Between invasive and noninvasive pituitary adenomas, the difference of nucleostemin expression was extremely significant (P〈0.01), and Ki-67 labeling index (LI) was also significantly different (P〈0.05). The difference of Ki-67LI between recurrent and non-recurrent groups was significant (P〈0.05). There was a positive correlation between nucleostemin gene and Ki-67LI levels (r =0.237, P〈0.05). Conclusions Nucleostemin gene plays an important roles in the invasion of human pituitary adenoma. Expression of nucleostemin gene is positively related to Ki-67 antigen expression, and both may be the valid clinical detection markers for assessing proliferation, invasion and recurrence of pituitary adenomas.
出处 《中华神经医学杂志》 CAS CSCD 2008年第4期343-346,共4页 Chinese Journal of Neuromedicine
关键词 垂体腺瘤 NUCLEOSTEMIN KI-67 逆转录聚合酶联反应 Pituitary adenoma Nucleostemin Ki-67 RT-PCR
  • 相关文献

参考文献11

  • 1Tsai RY, McKay RD. A nucleolar mechanism controlling cell proliferation in stem cells and cancer cells[J]. Genes Dev, 2002, 16 (23): 2991-3003.
  • 2Tsai RY, McKay RD. A multistep, GTP-driven mechanism controlling the dynamic cycling ofnucleostemin [J]. J Cell Biol, 2005, 168(2): 179-184.
  • 3Bemardi R, Pandolfi PP. The nucleolus: at the stem of immortality [J]. Nat Med, 2003, 9(1): 24-25.
  • 4Meng L, Zhu Q, Tsai RY. Nucleolar trafficking of nucleostemin family proteins: common versus protein-specific mechanisms [J]. Mol Cell Biol, 2007, 27(24): 8670-8682.
  • 5Yasumoto H, Meng L, Lin T, et al. GNL3L inhibits activity of estrogen-related receptor gamma by competing for coactivator binding[J]. J Cell Sci, 2007, 120(Pt 15): 2532-2543.
  • 6Meng L, Yasumoto H, Tsai RY, et al. Multiple controls regulate nucleostemin partitioning between nucleolus and nucleoplasm[J]. J Cell Sci, 2006, 119(Pt 24): 5124-5136.
  • 7Sijin L, Ziwei C, Yajun L, et al. The effect of knocking-down nucleostemin gene expression on the in vitro proliferation and in vivo tumorigenesis of HeLa cells[J]. J Exp Clin Cancer Res, 2004, 23(3): 529-538.
  • 8Wolfsberger S, Kitz K, Wunderer J, et al. Multiregional sampling reveals a homogenous distribution of Ki-67 proliferation rate in pituitary adenomas [J]. Acta Neurochir (Wien), 2004, 146 (12): 1323-1327.
  • 9Honegger J, Prettin C, Feuerhake F, et al. Expression of Ki-67 antigen in nonfunctioning pituitary adenomas: correlation with growth velocity and invasiveness [J]. J Neurosurg, 2003, 99 (4): 674-679.
  • 10Wolfsberger S, Wunderer J, Zachenhofer I, et al. Expression of cell proliferation markers in pituitary adenomas-correlation and clinical relevance of MIB-1 and anti-topoisomerase-11alpha[J]. Acta Neurochir (Wien), 2004, 146(8): 831-839.

同被引文献20

  • 1蔡子微,刘思金,孙丽秋,劳为德.Nucleostemin特异性RNA干扰对HeLa细胞体内外增殖能力的影响[J].中国病理生理杂志,2005,21(7):1331-1335. 被引量:14
  • 2周崧,江基尧.垂体腺瘤的分子病因学研究进展[J].中华神经医学杂志,2007,6(8):856-858. 被引量:1
  • 3Durkin ME,Yuan BZ,Zhou X,et al.DLC-1:a Rho GTPase-activating protein and tumour suppressor[J].J Cell Mol Med,2007,11(5):1185-1207.
  • 4Shimizu M,Saitoh Y,Itoh H.Immunohistochemical staining of Ha-ras oncogene product in normal,benign,and malignant human pancreatic tissues[J].Hum Pathol,1990,21(6):607-612.
  • 5Livak K J,Schmittgen TD.Analysis of relative gene expression data using real-time quantitative pcr and the 2(-delta delta c(t)) method[J].Methods,2001,25(4):402-408.
  • 6Asa SL,Ezzat S.The pathogenesis of pituitary tumors[J].Annu Rev Pathol,2009,4(1):97-126.
  • 7Yuan BZ,Miller M J,Keck CL,et al.Cloning,characterization,and chromosomal localization of a gene frequently deleted in human liver cancer (DLC-1) homologous to rat RhoGAP[J].Cancer Res,1998,58(10):2196-2199.
  • 8Kim TY,Vigil D,Der CJ,et al.Role of DLC-1,a tumor suppressor protein with RhoGAP activity,in regulation of the cytoskeleton and cell motility[J].Cancer Metastasis Rev,2009,28(1-2):77-83.
  • 9Ullmannova V,Popescu NC.Expression profile of the tumor suppressor genes dlc-1 and dlc-2 in solid tumors[J].Int J Oncol,2006,29(5):1127-1132.
  • 10Hankins GR,Sasaki T,Lieu AS,et al.Identification of the deleted in liver cancer 1 gene,dlcl,as a candidate maningioma tumor suppressor[J].Neurosurgery,2008,63(4):771-780.

引证文献2

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部